Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug Properties.

chemical glycosylation human complex-type oligosaccharide octreotide somatostatin (SRIF) somatostatin receptor subtype (sst)

Journal

Chemistry (Weinheim an der Bergstrasse, Germany)
ISSN: 1521-3765
Titre abrégé: Chemistry
Pays: Germany
ID NLM: 9513783

Informations de publication

Date de publication:
02 Jun 2023
Historique:
received: 13 01 2023
medline: 5 6 2023
pubmed: 23 3 2023
entrez: 22 3 2023
Statut: ppublish

Résumé

Somatostatin (somatotropin release-inhibiting factor, SRIF) is a growth hormone inhibitory factor in the form of a 14- or 28-amino acid peptide. SRIF affects several physiological functions through its action on five distinct SRIF receptor subtypes (sst1-5). Native SRIF has only limited clinical applications due to its rapid degradation in plasma. To overcome this obstacle, we have developed glycosylated SRIF analogues that possess not only metabolic stability but also high affinity to all five receptor subtypes by attaching human complex-type oligosaccharides. Such glycosylated SRIF analogues with improved pharmacokinetic profiles could be potent and novel therapeutic drugs for SRIF-related diseases in which several SRIF receptor subtypes are closely involved, and also shed light on new indications. Our results show that chemical glycosylation can be a powerful tool for the development of peptide and protein analogues superior to the original molecules with enhanced drug properties.

Identifiants

pubmed: 36945747
doi: 10.1002/chem.202300111
doi:

Substances chimiques

Receptors, Somatostatin 0
Somatostatin 51110-01-1
Polysaccharides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202300111

Subventions

Organisme : GlyTech, Inc.

Informations de copyright

© 2023 Wiley-VCH GmbH.

Références

J. L. Lau, M. K. Dunn, Bioorg. Med. Chem. 2018, 26, 2700-2707.
K. Fosgerau, T. Hoffman, Drug Discov. 2015, 20, 122-128.
 
L. H. Brinckerhoff, V. V. Kalashnikov, L. W. Thompson, G. V. Yamshchikov, R. A. Pierce, H. S. Galavotti, V. H. Engelhard, C. L. Slingluff Jr., Int. J. Cancer 1999, 83, 326-334;
A. Rozek, J.-P. S. Powers, C. L. Friedrich, R. E. W. Hancock, Biochemistry 2003, 42, 14130-14138;
B. S. Osborn, L. Sekut, M. Corcoran, C. Poortman, B. Sturm, G. Chen, D. Mather, H. L. Lin, T. J. Parry, Eur. J. Pharm. 2002, 456, 149-158;
E. M. Bech, S. L. Pedersen, K. J. Jensen, ACS Med. Chem. Lett. 2018, 9, 577-580;
J. M. Harris, R. B. Chess, Nat. Rev. Drug Discovery 2003, 2, 214-221.
R. Apweiler, H. Hermjakob, N. Sharon, Biochim. Biophys. Acta 1999, 1473, 4-8.
A. Varki, Glycobiology 2017, 27, 3-49.
 
I. Sakamoto, K. Tezuka, K. Fukae, K. Ishii, K. Taduru, M. Maeda, M. Ouchi, K. Yoshida, Y. Nambu, J. Igarashi, N. Hayashi, T. Tsuji, Y. Kajihara, J. Am. Chem. Soc. 2012, 134, 5428-5431;
H. Ochiai, K. Yoshida, H. Shibutani, A. Kanatani, Y. Nishiuchi, Chem. Pharm. Bull. 2019, 67, 236-243.
M. Theodoropoulou, G. K. Stalla, Front. Neuroendocrinol. 2013, 34, 228-252.
D. Cuevas-Ramos, M. Fleseriu, J. Mol. Endocrinol. 2014, 52, R223-R240.
D. Cuevas-Ramos, M. Fleseriu, Drug Des. Dev. Ther. 2016, 10, 227-239.
A. Helenius, M. Aebi, Annu. Rev. Biochem. 2004, 73, 1019-1049.
 
S. Thobhani, C.-T. Yuen, M. J. A. Bailey, C. Jones, Glycobiology 2009, 19, 201-211;
S. S. Park, J. Park, J. Ko, L. Chen, D. Meriage, J. Crouse-Zeineddini, W. Wong, B. A. Kerwin, J. Pharm. Sci. 2009, 98, 1688-1699.
 
M. R. Pratt, C. R. Bertozzi, Chem. Soc. Rev. 2005, 34, 58-68;
L. Liu, C. S. Bennett, C.-H. Wong, Chem. Commun. 2006, 21-33;
H. Hojo, Y. Nakahara, Pept. Sci. 2007, 88, 23-48;
C. Unverzagt, Y. Kajihara, Chem. Soc. Rev. 2013, 42, 4408-4420;
J. D. Lin, X.-W. Liu, Chem. Asian J. 2020, 15, 2548-2557.
Y. Kajihara, Y. Suzuki, N. Yamamoto, K. Sasaki, T. Sakakibara, L. R. Juneja, Chem. Eur. J. 2004, 10, 971-985.
N. Yamamoto, Y. Ohmori, T. Sakakibara, K. Sasaki, L. R. Juneja, Y. Kajihara, Angew. Chem. Int. Ed. 2003, 42, 2537-2540;
Angew. Chem. 2003, 115, 2641-2644.
N. Yamamoto, T. Sakakibara, Y. Kajihara, Tetrahedron Lett. 2004, 45, 3287-3290.
H. Tanaka, T. Tsunoda, I. Nukaya, A. Sette, K. Matsuda, Y. Umano, H. Yamaue, K. Takesako, H. Tanimura, Br. J. Cancer 2001, 84, 94-99.
G. G. Glenner, C. W. Wong, Biochem. Biopys. Res. Commun. 1984, 120, 885-890.
B. A. Yankner, L. K. Duffy, D. A. Kirschner, Science 1990, 250, 279-282.
H. Naiki, K. Higuchi, M. Hosokawa, T. Takeda, Anal. Biochem. 1989, 177, 244-249.
 
M. A. Hossain, R. Okamoto, J. A. Karas, P. Praveen, M. Liu, B. E. Forbes, J. D. Wade, Y. Kajihara, J. Am. Chem. Soc. 2020, 142, 1164-1169;
M. Liu, P. Zhao, M. H. Uddin, W. Li, F. Lin, C. Chandrashekar, Y. Nishiuchi, Y. Kajihara, B. E. Forbes, D. Wootten, J. D. Wade, M. A. Hossain, Bioconjugate Chem. 2021, 32, 2148-2153.
C. Chandrashekar, M. A. Hossain, J. D. Wade, Front. Chem. 2021, 9, 650025.
A. M. Sinclair, S. Elliottg, J. Pharm. Sci. 2005, 94, 1626-1635.
 
J. Eng, W. A. Kleinman, L. Singh, G. Singh, J. P. Raufman, J. Biol. Chem. 1992, 267, 7402-7405;
J. M. Egan, A. R. Clocquet, D. Elahi, J. Clin. Endocrinol. Metab. 2002, 87, 1282-1290.
Y. Kajihara, T. Tsuji, Y. Nambu, K. Ishii, K. Yoshida, K. Tezuka, WO2011052523 A1, 2011.
H. Hibino, Y. Miki, Y. Nishiuchi, J. Pept. Sci. 2012, 18, 763-769.
 
B. Kamber, A. Hartmann, K. Eisler, B. Riniker, H. Rink, P. Sieber, W. Rittel, Helv. Chim. Acta 1980, 63, 899-915;
E. V. Kudryavtseva, M. V. Sidorova, M. V. Ovchinnikov, Zh. D. Bespalova, V. N. Bushuev, J. Pept. Res. 1997, 49, 52-58.
 
Y. Fujiwara, K. Akaji, Y. Kiso, Chem. Pharm. Bull. 1994, 42, 724-726;
H. Hibino, Y. Nishiuchi, Org. Lett. 2012, 14, 1926-1929.
Y.-C. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099-3108.
K. Öberg, L. Kvols, M. Caplin, G. D. Fave, W. der Herder, G. Rindi, P. Ruszniewski, E. A. Woltering, B. Wiedenmann, Ann. Oncol. 2004, 15, 966-973.
M. A. Sheridan, J. D. Kittilson, B. J. Slagter, Amer. Zool. 2000, 40, 269-286.
H. A. Schmid, P. Schoeffter, Neuroendocrinology 2004, 80 Suppl 1, 47-50.
R. Urso, P. Blardi, G. Giorgi, Eur. Rev. Med. Pharmacol. Sci. 2002, 6, 33-44.
A. L. T. Sørensen, H. Clausen, H. H. Wandall, Biochim. Biophys. Acta 2012, 1820, 1797-1808.
 
A. Ogura, T. Tahara, S. Nozaki, K. Morimoto, Y. Kizuka, S. Kitazume, M. Hara, S. Kojima, H. Onoe, A. Kurbangalieva, N. Taniguchi, Y. Watanabe, K. Tanaka, Sci. Rep. 2016, 6, 21797;
I. Smirnov, R. Sibgatullina, S. Urano, T. Tahara, P. Ahmadi, Y. Watanabe, A. R. Pradipta, A. Kurbangalieva, K. Tanaka, Small 2020, 16, 2004831.
L. Yuan, J. Wang, W. Shen, Pharm. Res. 2005, 22, 220-227.

Auteurs

Hirofumi Ochiai (H)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.

Taiji Shimoda (T)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.

Kazuhiro Fukae (K)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
Otsuka Chemical Co., Ltd., 463 Kagasuno, Kawauchi-cho, Tokushima, 771-0193, Japan.

Masatoshi Maeda (M)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
Taiho Pharmaceutical Co., Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo, 101-8444, Japan.

Kazuyuki Ishii (K)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.

Kenta Yoshida (K)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
Earth Corporation, 3218-12 Sakoshi, Ako City, Hyogo, 678-0192, Japan.

Katsunari Tezuka (K)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
Skinscience Laboratory, Ands Corporation, 9-3-7 Tanimachi, Chuo-ku, Osaka, 542-0012, Japan.

Keisuke Tazuru (K)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., 5-1-35 Saito-aokita, Minoh, Osaka, 562-0029, Japan.

Hayato Saijo (H)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
Otsuka Chemical Co., Ltd., 463 Kagasuno, Kawauchi-cho, Tokushima, 771-0193, Japan.

Hiroaki Asai (H)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.

Akio Kanatani (A)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.

Yuji Nishiuchi (Y)

GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
Graduate School of Science, Tohoku University, 6-3 Aramaki Aza-Aoba, Aoba-ku, Sendai, 980-8578, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH